The Oxford Vaccine Group’s Com-Cov vaccine trial is studying the use of different combinations of approved COVID-19 vaccines for the first and second immunisation doses.
This study is being led by the Oxford Vaccine Group (Chief Investigator Professor Matthew Snape), and delivered by a network of trial sites across the UK. The study is funded by the Vaccine Task Force, National Institute for Health Research (NIHR) and the Coalition for Epidemic Preparedness Innovations (CEPI).
Our researchers are working hard to get the results available to inform UK immunisation policy as quickly as possible. We ask that the media do not continue to contact researchers while this critical work is underway, and to use the media contact form for press enquiries.